We use cookies to improve the user experience and gather anonymous visitor statistics. By using our website, you agree to the use of cookies.

Facebook
LinkedIn

Search for:

Product
Research & References
News & Media
About AroCell
Investors
Contact
To Order

Product
Research & References
News & Media
About AroCell
Investors
Contact
To Order

Search for:

News
Newsletter
- Featured Articles
- Newsletter Subscribe
Events
Media

Nasdaq News Release

1 July 2016

Nasdaq has issued a News Release to welcome AroCell to First North
Please follow the enclosed link for the official document:
20160630_AroCell_FINAL

Categories

News
Press Releases

Latest posts

AroCell tecknar distributörsavtal med Gongyingshi i Kina för AroCell TK 210 ELISA
15 January 2019
AroCell signs distribution agreement with Gongyingshi in China for AroCell TK 210 ELISA
15 January 2019
AroCell tecknar distributörsavtal med Eurobio Scientific i Frankrike
20 December 2018
AroCell signs distribution agreement with Eurobio Scientific in France
20 December 2018
Ny vetenskaplig artikel från AroCell som konfirmerar värdet av TK 210 ELISA som verktyg inom läkemedelsutveckling och pre-klinisk forskning
11 December 2018

Archive

2019
- AroCell tecknar distributörsavtal med Gongyingshi i Kina för AroCell TK 210 ELISA
  15 January 2019
- AroCell signs distribution agreement with Gongyingshi in China for AroCell TK 210 ELISA
  15 January 2019
2018
- AroCell tecknar distributörsavtal med Eurobio Scientific i Frankrike
  20 December 2018
- AroCell signs distribution agreement with Eurobio Scientific in France
  20 December 2018
- Ny vetenskaplig artikel från AroCell som konfirmerar värdet av TK 210 ELISA som verktyg inom läkemedelsutveckling och pre-klinisk forskning
  11 December 2018
- A new scientific publication from AroCell confirming the value of AroCell TK 210 ELISA as a tool in drug discovery and development
  11 December 2018
- AroCell presenterar resultat från U-CAN TK1 lymfomstudien samt från en studie där TK 210™ ELISA jämförs med andra metoder
  27 November 2018
- AroCell presents results from the U-CAN TK1 lymphoma study and from a comparison study between TK 210™ ELISA and other assays
  27 November 2018
- AroCells valberedning har haft sitt första möte
  20 November 2018
- Delårsrapport 1 januari – 30 september 2018
  14 November 2018
- Arocell utser Michael Brobjer till ny VD
  23 October 2018
- AroCell AB announces the appointment of a new CEO
  23 October 2018
- Patent godkänt på den amerikanska marknaden
  17 October 2018
- Patent granted in the US
  17 October 2018
- Ytterligare ett abstract som visar värdet av AroCells provberedningssteg i samband med diagnostik har accepterats av ISOBM inför mötet i Hamburg
  9 October 2018
- A second abstract accepted at ISOBM in Hamburg demonstrating enhanced diagnostic value when using AroCell’s proprietary sample preparation method
  9 October 2018
- TK 210 ELISA jämfört med andra metoder
  18 September 2018
- TK 210 ELISA compared to other methods
  18 September 2018
- Delårsrapport 1 januari – 30 juni 2018
  31 August 2018
- Anders Hultman ny CFO för AroCell
  30 August 2018
- Patent förstärker AroCells möjligheter på den amerikanska marknaden
  29 August 2018
- Patent reinforces AroCell’s opportunities in the US market
  29 August 2018
- New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker
  24 August 2018
- AroCell rekryterar ny CFO
  10 July 2018
- 2018-06-15 Kommuniké från årsstämma
  15 June 2018
- Arocell rekryterar ny VD
  22 May 2018
- Sista dag för handel med BTA den 22 maj 2018
  17 May 2018
- Kallelse till årsstämma i Arocell AB (publ)
  15 May 2018
- AroCell: Företrädesemissionen i AroCell övertecknad
  3 May 2018
- AroCell offentliggör ett andra tilläggsprospekt
  27 April 2018
- Delårsrapport
  1 januari – 31 mars 2018
  27 April 2018
- AroCell tecknar licensavtal med Roche – kommentarer från AroCell’s vd
  25 April 2018
- AroCell announces license agreement with Roche
  24 April 2018
- AroCell tecknar globalt licensavtal med Roche
  24 April 2018
- AroCell offentliggör tilläggsprospekt
  17 April 2018
- AroCell offentliggör pågående förhandling om utlicensiering och samarbete med stort diagnostikbolag, upprättar tilläggsprospekt och förlänger teckningstiden
  6 April 2018
- Idag inleds teckningstiden i AroCell ABs (publ) företrädesemission om cirka 35 MSEK
  26 March 2018
- AroCell offentliggör prospekt, teaser och anmälningssedel
  20 March 2018
- AroCell beslutar om en företrädesemission om cirka 35 MSEK (säkerställd/garanterad till 75 %) i syfte att tillföra kapital för klinisk validering, kommersialisering samt licensiering och partnerskap
  12 March 2018
- Nya resultat med TK 210™ ELISA kommer att presenteras på AACR 2018, 14 – 19 April i Chicago.
  8 March 2018
- AroCell TK 210 ELISA presented at LabRoots Drug Discovery Virtual Congress February 21-22, 2018
  1 March 2018
- AroCell Delårsrapport 1 oktober – 31 december 2017
  22 February 2018
- Länk till ProHearings I Stockholm
  20 February 2018
- AroCell på ProHearings I Stockholm
  13 February 2018
- AroCells valberedning har haft sitt första möte
  9 February 2018
- AroCell på rätt väg!
  23 January 2018
- AroCell på den asiatiska marknaden
  18 January 2018
- Blodprov förbättrar cellbehandlingen
  18 January 2018
2017
- Julhälsning
  22 December 2017
- AroCell AB (publ) signs Letter of Intent with Korean-based company, Green Cross Cell Corporation.
  22 November 2017
- AroCell AB (publ) Interim Report, Q3 2017
  22 November 2017
- Webinar recording is now available
  20 November 2017
- Abstract published presenting AroCell TK 210 ELISA from the PROMIX study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017
  8 November 2017
- AroCell poster presentations at 2017 NCRI Cancer Conference
  1 November 2017
- AroCell AB: announces that a distribution agreement has been signed with Pathway Diagnostics Ltd, for distribution of the AroCell TK 210 ELISA test in United Kingdom and Ireland.
  13 October 2017
- AroCell Research Poster on TK1 / TK 210 ELISA in Prostate Cancer has been accepted for presentation at the UK National Cancer Research Institute (NCRI) Annual Meeting November 2017
  26 September 2017
- AroCell TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium
  22 September 2017
- Webinar announcement and invitation
  20 September 2017
- New application for AroCell TK 210 ELISA opens new opportunities for drug development research
  18 September 2017
- AroCell AB Interim Report, Q2 2017
  24 August 2017
- TK 210 ELISA appears in latest issue Genetic Engineering & Biotechnology News
  7 August 2017
- Beslut vid årsstämman i AroCell AB (publ) 2017
  18 May 2017
- AroCell AB (publ) Interim report for period 1 January – 31 March 2017
  11 May 2017
- AroCell Presentation at 13th Annual Biomarkers & Immuno-Oncology World Congress 2017 in Philadelphia
  19 April 2017
- KALLELSE TILL ÅRSSTÄMMA I AROCELL AB (PUBL)
  13 April 2017
- AroCell TK 210 ELISA Webinar Recording is now available!
  28 March 2017
- AroCell AB (publ) Year-End Report
  16 February 2017
- AroCell research poster on prostate cancer has been accepted by American Association for Cancer Research (AARC)
  24 January 2017
- Nomination committee appointed for Annual General Meeting 2017
  19 January 2017
2016
- Announcement – AroCell AB PR and Marketing Communications Manager
  19 December 2016
- Interim report January – September 2016
  17 November 2016
- Ann Hammarstrand appointed as new CFO to AroCell
  3 November 2016
- AroCell signs distribution agreement with Eagle Biosciences in the United States
  6 October 2016
- New TK 210 ELISA product presentation
  2 October 2016
- Oral presentation today of TK 210 ELISA abstract at ISOBM, Chicago
  4 September 2016
- Interim report January – June 2016
  25 August 2016
- Improved measurement of Thymidine Kinase 1 within the normal range due to improved composition of the zero calibrator.
  12 August 2016
- Nasdaq News Release
  1 July 2016
- AroCell is approved for listing on the Nasdaq First North and publishes Corporate description
  28 June 2016
- AroCell applying for listing on the Nasdaq First North exchange
  21 June 2016
- Christine Tadgell new board member in AroCell
  23 May 2016
- CEO Jan Stålemark’s presentation at the AGM 2016
  19 May 2016
- Report from the Annual General Meeting of AroCell
  19 May 2016
- AroCell Newsletter for May is now available
  11 May 2016
- Interim report January – March 2016
  10 May 2016
- Leading profile in biomarkers joins the AroCell management team
  2 May 2016
- New patent strengthens the AroCell patent portfolio
  28 April 2016
- Annual Report 2015
  27 April 2016
- New clinical study with promising results for the TK 210 ELISA test from AroCell
  18 April 2016
- Kallelse till årsstämma i AroCell AB (publ)
  18 April 2016
- Final call for trading with BTA
  8 January 2016
2015
- Nomination committee appointed for Annual General Meeting 2016
  17 December 2015
- Oversubscription of preferential rights issue
  8 December 2015
- Sign up for our Newsletter!
  8 December 2015
- Presentation by CEO Jan Stålemark at Redeye Investor Forum, December 1
  2 December 2015
- Interview with CEO Jan Stålemark for Analysguiden, November 2015
  30 November 2015
- Presentation from Stora Aktiedagen Göteborg, November 23
  30 November 2015
- AroCell announces prospectus, teaser and application form
  17 November 2015
- Progress for development of prostate treatment, results from STHLM3 presented today
  10 November 2015
- AroCell announces interim report three will be brought forward
  6 November 2015
- Announcement of fully guaranteed preferential rights issue of approximately 52.2 MSEK
  6 November 2015
- Continued expansion to AroCell organization
  23 October 2015
- AroCell presents a robust TK1 blood-test at an international biomarker meeting
  19 October 2015
- Clarification regarding press release about CE marking
  2 October 2015
- AroCell announces that it has filed for the CE-mark registration of TK 210 ELISA
  1 October 2015
- AroCell announces achievement of critical milestone: successful phase 1 review of TK 210 ELISA production process.
  17 August 2015
- AroCell recognized by EU Commission and Horizon 2020 Program Committee
  13 August 2015
- AroCell strengthens the organization
  5 June 2015
- Report from the annual general meeting of AroCell
  3 June 2015
- Notice of annual general meeting of AroCell AB (publ)
  6 May 2015
- Schedule revision providing for CE-mark during third quarter 2015
  12 February 2015
- Revised schedule means CE-marking during the third quarter of 2015
  12 February 2015
2014
- New clinical study with promising results
  29 October 2014

Newsletter

Product
Research & References
News & Media
About AroCell
Investors
Contact
To Order

Facebook
LinkedIn

AroCell AB Uppsala Business Park
Virdings allé 32 B SE-754 50 Uppsala Sweden

info@arocell.com
018-50 30 20

Privacy Policy

© 2019 AroCell AB. All rights reserved.

All of the information appearing on this website is not intended to be used for medical diagnosis or treatment. Information provided on this website does not either constitute medical and/or other professional advice.
TK 210 ELISA is CE-marked and registered by the Swedish Medical Products Agency.